Table 6 Utilisation of lipid lowering medications among T2DM patients
Variable | Baseline | Follow up | Mean difference (95% CI) | p value | % difference |
|---|---|---|---|---|---|
TC (mmol/l) | |||||
 No statin | 5.03 ± 0.12 | 4.95 ± 0.13 | −0.07 (−0.42 to 0.28) | 0.6817 | 1.39 |
 Atorvastatin | 4.06 ± 0.16 | 4.13 ± 0.16 | 0.07 (−0.37 to 0.51) | 0.7434 | 1.72 |
TG (mmol/l) | |||||
 No statin | 1.32 ± 0.06 | 1.19 ± 0.06 | −0.13 (−0.30 to 0.04) | 0.1322 | 9.85 |
 Atorvastatin | 1.14 ± 0.06 | 0.93 ± 0.06 | −0.21 (−0.39 to −0.03) | 0.0259 | 18.42 |
HDL-c (mmol/l) | |||||
 No statin | 1.36 ± 0.03 | 1.05 ± 0.03 | −0.30 (−0.39 to −0.21) | <0.0001 | 22.06 |
 Atorvastatin | 1.36 ± 0.04 | 1.04 ± 0.04 | −0.31 (−0.42 to −0.19) | <0.0001 | 22.79 |
Non-HDL (mmol/l) | |||||
 No statin | 3.67 ± 0.11 | 3.89 ± 0.12 | 0.23 (−0.09 to 0.55) | 0.1617 | 6.27 |
 Atorvastatin | 2.69 ± 0.15 | 3.09 ± 0.15 | 0.39 (−0.04 to 0.81) | 0.0754 | 14.50 |
LDL-c (mmol/l) | |||||
 No statin | 3.06 ± 0.11 | 3.36 ± 0.11 | 0.30 (−0.01 to 0.60) | 0.058 | 9.80 |
 Atorvastatin | 2.19 ± 0.15 | 2.68 ± 0.14 | 0.47 (0.06 to 0.87) | 0.022 | 21.46 |
CR | |||||
 No statin | 5.24 ± 0.15 | 5.57 ± 0.49 | 0.33 (−0.68 to 1.34) | 0.5202 | 6.29 |
 Atorvastatin | 4.31 ± 0.19 | 4.32 ± 0.20 | 0.02 (−0.53 to 0.57) | 0.9547 | 0.46 |
VLDL-c (mmol/l) | |||||
 No statin | 0.60 ± 0.03 | 0.58 ± 0.05 | −0.01 (−0.12 to 0.09) | 0.8181 | 1.67 |
 Atorvastatin | 0.52 ± 0.03 | 0.42 ± 0.03 | −0.09 (−0.18 to −0.01) | 0.0237 | 17.3 |